* THROMBOGENICS INITIATES PHASE 2 CLINICAL STUDY EVALUATING ANTI-PLGF (THR-317) IN COMBINATION WITH ANTI-VEGF (RANIBIZUMAB) FOR TREATMENT OF DIABETIC MACULAR EDEMA (DME)
from Reuters: Company News https://ift.tt/2r18UBI
via IFTTT
from Reuters: Company News https://ift.tt/2r18UBI
via IFTTT
Post a Comment